Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 717-723

  Almond, David ^a   Kimura, Tetsuya ^b   Kong, Xiangpeng ^a   Swetnam, James ^a   Zolla Pazner, Susan ^a,c   Cardozo, Timothy ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONFORMATION; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSEUDOTYPING; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS TYPING; CHEMICAL STRUCTURE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

CONSERVED SEQUENCE; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY;

EID: 77954191991     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0254     Document Type: Article

References (34)

1. Huang C, TangM, Zhang M, et al.: Structure of a V3-containing HIV-1 gp120 core. Science 2005;310(5750):1025-1028.
2. Lo Conte L, Ailey B, Hubbard T, Brenner S, Murzin A, and Chothia C: SCOP: A structural classification of proteins database. Nucleic Acids Res 2000;28(1):257-259.
3. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody- sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996;384(6605):184- 187.
4. Hill C, Deng H, Unutmaz D, et al.: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997;71(9): 6296-6304.
5. Leitner T, Foley B, Hahn B, et al., eds. HIV Sequence Compendium. Los Alamos National Laboratory, NM: Theoretical Biology and Biophysics Group, 2005, No. LA-UR 06-0680.
6. Burke V, Williams C, Sukumaran M, et al.: Structural basis of the cross-reactivity of genetically related human anti-HIV-1 monoclonal antibodies: Potential implications for design of V3 based immunogens. Structure 2009;17(11):1538-1546.
7. Stanfield R, Gorny M, Williams C, Zolla-Pazner S, and Wilson I: Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004;12(2):193-204.
8. Stanfield R, Gorny M, Zolla-Pazner S, and Wilson I: Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 crossreactivity. J Virol 2006;80(12):6093-6105.
9. Bell C, Pantophlet R, Schiefner A, et al.: Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 2008; 375(4):969-978.
10. Dhillon A, Stanfield R, Gorny M, Williams C, Zolla-Pazner S, and Wilson I: Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr D Biol Crystallogr 2008;D64(Pt 7):792-802.
11. Page KA, Landau NR, and Littman DR: Construction and use of a human-immunodeficiency-virus vector for analysis of virus infectivity. J Virol 1990;64(11):5270-5276.
12. Connor RI, Chen BK, Choe S, and LandauNR: VPR is required for efficient replication of human-immunodeficiency-virus type-1 in mononuclear phagocytes. Virology 1995;206(2):935-944.
13. He J, Choe S, Walker R, Di Marzio P, Morgan D, and Landau N: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995;69(11):6705-6711.
14. Smith AJ, Cho MI, Hammarskjold ML, and Rekosh D: Human immunodeficiency virus type 1 Pr55gag and Pr160gagpol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol 1990;64(6):2743-2750.
15. Rekosh D, Nygren A, Flodby P, Hammarskjold ML, and Wigzell H: Coexpression of human immunodeficiency virus envelope proteins and tat from a single simian-virus 40 late replacement vector. Proc Natl Acad Sci USA 1988;85(2):334-338.
16. Declercq E, Yamamoto N, Pauwels R, et al.: Highly potent and selective-inhibition of human-immunodeficiency-virus by the bicyclam derivative JM3100. AntimicrobAgents Chemother 1994;38(4):668-674.
17. Bridger GJ, Skerlj RT, Thornton D, et al.: Synthesis and structure-activity-relationships of phenylenebis(methylene)- linked bis-tetraazamacrocycles that inhibit HIV replication- effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 1995;38(2):366-378.
18. Hendrix CW, Flexner C, MacFarland RT, et al.: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44(6):1667-1673.
19. Baba M, Nishimura O, Kanzaki N, et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96(10): 5698-5703.
20. Dragic T, Trkola A, Thompson DAD, et al.: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97(10):5639-5644.
21. Bjorndal A, Deng HK, Jansson M, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71(10): 7478-7487.
22. Jeffs SA, Gorny MK, Williams C, et al.: Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett 2001;79(3):209-213.
23. Gorny MK, Conley AJ, Karwowska S, et al.: Neutralization of diverse human-immunodeficiency-virus type-1 variants by an anti-V3 human monoclonal-antibody, 447-52D. J Virol 1992;66(12):7538-7542.
24. Gorny MK, VanCott TC, Hioe C, et al.: Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol 1997;159(10):5114-5122. (Pubitemid 127471052)
25. Gigler A, Dorsch S, Hemauer A, et al.: Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999;73(3):1974-1979.
26. Nyambi PN, Nkengasong J, Peeters M, et al.: Reduced capacity of antibodies from patients infected with humanimmunodeficiency- virus type-1 (HIV-1) group-O to neutralize primary isolates of HIV-1 group-M viruses. J Infect Dis 1995;172(5):1228-1237.
27. Almond D, Tetsuya K, Kong X, Zolla-Pazner S, and Cardozo T: Dynamic characterization of the V3 loop crown. Antiviral Ther 2007;12(Suppl 4):P13-31.
28. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, and Zolla-Pazner S: Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23(3):415-426.
29. Gorny M, Williams C, Volsky B, et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 2002;76(18):9035-9045.
30. Gorny M, Xu J, Karwowska S, Buchbinder A, and Zolla- Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150(2):635-643.
31. Pantophlet R, Aguilar-Sino R, Wrin T, Cavacini L, and Burton D: Analysis of the neutralization breadth of the anti- V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 2007;364(2): 441-453.
32. Zolla-Pazner S, Cohen S, Pinter A, et al.: Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009;392(1):82-93.
33. Zolla-Pazner S, Cohen SS, Krachmarov C, Wang SX, Pinter A, and Lu S: Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008;372(2):233-246.
34. Kaur H and Raghava GPS: An evaluation of beta-turn prediction methods. Bioinformatics 2002;18(11):1508-1514.